Premium
An agenda for UK clinical pharmacology: Pharmacoeconomics
Author(s) -
Hughes Dyfrig A.
Publication year - 2012
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2012.04247.x
Subject(s) - pharmacoeconomics , economic evaluation , medicine , health economics , stakeholder , valuation (finance) , health care , clinical trial , cost–benefit analysis , quality adjusted life year , cost effectiveness , management science , actuarial science , public economics , intensive care medicine , risk analysis (engineering) , business , nursing , accounting , economics , public health , political science , management , economic growth , law , pathology
Pharmacoeconomics is an essential component of health technology assessment and the appraisal of medicines for use by UK National Health Service (NHS) patients. As a comparatively young discipline, its methods continue to evolve. Priority research areas for development include methods for synthesizing indirect comparisons when head‐to‐head trials have not been performed, synthesizing qualitative evidence (for example, stakeholder views), addressing the limitations of the EQ‐5D tool for assessing quality of life, including benefits not captured in quality‐adjusted life years (QALYs), ways of assessing valuation methods (for determining utility scores), extrapolation of costs and benefits beyond those observed in trials, early estimation of cost‐effectiveness (including mechanism‐based economic evaluation), methods for incorporating the impact of non‐adherence and the role of behavioural economics in influencing patients and prescribers.